Protein requirements in children during stress conditions;Apports proteiques chez l'enfant au cours des etats d'agression

Archives de Pediatrie

Volumn 6, Issue 8, 1999, Pages 872-881

  Beaufrere B ^b   Bresson, J L ^b   Briend, A ^b   Ghisolfi, J ^b   Goulet, O ^a   Navarro, J ^b   Putet, G ^b   Rey, J ^b   Ricour, C ^b   Rieu, D ^b   Turck, D ^b   Vidailhet, M ^b  

^a HÔPITAL NECKER ENFANTS MALADES   (France)

^b NONE

Author keywords

Critically ill children; Protein metabolism; Protein requirements; Stress conditions

Indexed keywords

CALORIC INTAKE; CHILD NUTRITION; CRITICAL ILLNESS; HUMAN; NUTRITIONAL REQUIREMENT; PROTEIN INTAKE; PROTEIN METABOLISM; REVIEW; STRESS;

EID: 0033178114     PISSN: 0929693X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0929-693X(00)88483-3     Document Type: Article

References (105)

1. 1 Tomkins AM, Garlick PJ, Schofield WN, Waterlow JC. The combined effects of infection and malnutrition on protein metabolism in children. Clin Sci 1983; 65 : 313-24.
2. 2 Pollack MM, Ruttiman UE, Willey JS. Nutritional depletion in critically ill children: associations with physiologic instability and increased quantity of care. J Parenter Enter Nutr 1985; 9 : 309-13.
3. 3 Manary MJ, Broadhead RL, Yarasheski KE. Whole-body protein kinetic in marasmus and kwashiorkor during acute infection. Am J Clin Nutr 1998; 67 : 1205-9.
4. 4 Kien CL, Young VR, Rohrbaugh DK, Burke JF. Increased rates of whole body protein synthesis and breakdown in children recovering from burns. Ann Surg 1978; 187 : 383-91.
5. 5 Alexander JW, MacMillan BG, Stinnett JD, Ogle CK, Bozian RC, Fischer JE, et al. Beneficial effects of aggressive protein feeding in severely burned children. Ann Surg 1980; 192 : 505-17.
6. 6 Winthrop AL, Wesson DE, Pencharz PB, Jacobs DG, Heim T, Filler RM. Injury severity, whole body protein turnover, and energy expenditure in pediatric trauma. J Pediatr Surg 1987; 22 : 534-7.
7. 7 Cunningham JJ, Lydon MK, Russel WE. Calorie and protein provision for recovery from severe burns in infants and young children. Am J Clin Nutr 1990; 51 : 553-7.
8. 8 Hildreth MA, Herndon DN, Parks DH, Desai MH, Rutan T. Evaluation of a caloric requirement formula in burned children treated with early excision. J Trauma 1987; 27 : 188-9.
9. 9 Cunningham JJ, Harris LJ, Briggs SE. Nutritional support of the severily burned infant. Nutr Clin Pract 1988; 3 : 69-73.
10. 10 Berclaz PY, Benedek C, Jequier E, Schutz Y. Changes in protein turnover and resting energy expenditure after treatment of malaria in gambian children. Pediatr Res 1996; 39 : 401-9.
11. 11 Benhariz M, Goulet O, Salas J, Colomb V, Ricour C. Energy cost of fever in children on total parenteral nutrition. Clin Nutr 1997; 16 : 251-5.
12. 12 Conférence de consensus, accréditée par l'ANAES. Nutrition de l'agressé. Jeudi 23 octobre 1997; Institut Gustave-Roussy. Société francophone de nutrition entérale et parentérale. Paris: Interligne; 1998. p. 6-7.
13. 13 Gelfand RA, Matthews DE, Bier DM, Shervin RS. Role of counterregulatory hormones in the catabolic reponse to stress. J Clin Invest 1984; 74 : 2238-48.
14. 14 Rennie MJ. Muscle protein turnover and the wasting due to injury and disease. Br Med Bull 1985; 41 : 257-64.
15. 15 Long CL, Birkhan RH, Geiger JW, Blakemore WS. Contribution of skeletal muscle protein in elevated rates of whole body protein catabolism in trauma patients. Am J Clin 1981; 34 : 1087-1093.
16. 16 Long CL, Jeevanandam M, Kim BM, Kinney JM. Whole body protein synthesis and catabolism in septic man. Am J Clin Nutr 1977; 30 : 1340-4.
17. 17 Wolfe RR, Goodenough RD, Burke JF, Wolfe MM. Response of protein and urea kinetics in burn patients to different level of protein intake. Ann Surg 1983; 197 : 163-71.
18. 18 Shaw JHF, Wildbore M, Wolfe RR. Whole body protein kinetics in severely septic patients. Ann Surg 1987; 205 : 288-94.
19. 19 Pearl RH, Clowes GHA, Hirsch EF, Loda M, Grindlinger GA, Wolfort S. Prognosis and survival as determined by visceral amino acid clearance in severe trauma. J Trauma 1985; 25 : 777-83.
20. 20 Fischer JE. A teological view of sepsis. Clin Nutr 1991; 10 : 1-9.
21. 21 Darmaun D. Métabolisme de la glutamine in vivo chez l'homme: implications pour la nutrition artificielle. Nutr Clin Métabol 1990; 4 : 203-14.
22. 22 Vinnars E, Bergstrom J, Furst P. Influence of the post operative state on the intracellular free amino acids in human muscle tissue. Ann Surg 1975; 182 : 665-70.
23. 23 Ligumsky M, Simon PL, Karmeli F, Rachmilewitz D. Role of interleukin-1 in inflammatory bowel disease: enhanced production during active disease. Gut 1990; 31 : 686-9.
24. 24 Chang HR, Bistrian B. The role of cytokines in the catabolic consequences of infection and injury. J Parenter Enter Nutr 1998; 22 : 156-66.
25. 25 Motil KJ, Grand RJ, Matthews DE, Bier DM, Maletskos CJ, Young VR. Whole body leucine metabolism in adolescents with Crohn's disease and growth failure during nutritional supplementation. Gastroenterology 1982; 82 : 1359-68.
26. 26 Powell-Tuck J, Garlick PJ, Lennard-Jones JE, Water JC. Rates of whole body protein synthesis and breakdown increase with the severity of inflammatory bowel disease. Gut 1984; 25 : 469-74.
27. 27 Thomas AG, Miller V, Taylor F, Maycock P, Scrimgeour CM, Rennie MJ. Whole body protein turnover in childhood Crohn's disease. Gut 1992; 33 : 675-7.
28. 28 Sheperd RW, Holttl, Johnson LP, Quirk P, Thomas BJ. Leucine metabolism and body cell mass in cystic fibrosis. Nutrition 1995; 11 : 138-41.
29. 29 Baur LA, Waters DL, Allen BJ, Blagejovic N, Gaskin KJ. Nitrogen depletion in malnourished children with cystic fibrosis. Am J Clin Nutr 1991; 53 : 503-11.
30. 30 MacAllan DC, McNurlan MA, Milne E, Calder AG, Garlick PJ, Griffin GE. Whole-body protein turnover from leucine kinetics and the response to nutrition in human immunodeficiency virus infection. Am J Clin Nutr 1995; 61 : 818-26.
31. 31 Kanof M, Lake AM, Bayless TM. Decreased height velocity in children and adolescents before the diagnosis of Crohn's disease. Gastroenterology 1988; 95 : 1523-7.
32. 32 Markowitz J, Grancher K, Rosa J, Aiges H, Daum F. Growth failure in pediatric inflammatory bowel disease. J Pediatr Gastroenterol Nutr 1993; 16 : 373-80.
33. 33 Motil KJ, Grand RJ, Davis-Kraft L, Ferlic LL, Smith EO. Growth failure in children with inflammatory bowel disease: a prospective study. Gastroenterology 1993; 105; 681-91.
34. 34 Suzuki Y, Saito H, Kasanuki J, Kishimoto T, Tamura Y, Yoshida S. Significant increase of interleukin-6 production in blood mononuclear leukocytes obtained from patients with active inflammatory bowel disease. Life Sci 1990; 47 : 2193-7.
35. 35 Murch SH, Lamkin VA, Savage MO, et al. Serum concentrations of tumor necrosis factor-α in childhood chronic inflammatory bowel disease. Gut 1991; 32 : 313-7.
36. 36 Stuart-Elborn J, Gorden SM, Western PJ. Tumor necrosis factor-α, resting energy expenditure, and cachexia in cystic fibrosis. Clin Sci 1993; 85 : 563-8.
37. 37 Roubenoff R, Roubenoff RA, Cannon JG, Kehayias JJ, Zhuang H, Dawson-Hughes B, et al. Rheumatoid cachexia: cytokine-driven hypermetabolism accompanying reduced body cell mass in chronic inflammation. J Clin Invest 1994; 93 : 2379-86.
38. 38 Fong Y, Moldawer LL, Marano M, Wei H, Barber A, Manogue K, Tracey KJ, et al. Cachectin/TNF or IL-1 alpha induces cachexia with redistribution of body proteins. Am J Physiol 1989; 256 : R659-65.
39. 39 Zamir O, Hasselgren PO, von Hallmen D, Fischer JE. In vivo administration of interleukin-1a induces muscle proteolysis in normal and adrenalectomized rats. Metabolism 1993; 42 : 204-8.
40. 40 Hoshino E, Pichard C, Greenwood CE, Kuo GC, Cameron RG, Kurian R, et al. Body composition and metabolic rate in rat during a continuous infusion of cachectin. Am J Physiol 1991; 260 : E27-36.
41. 41 De Benedetti F, Alonzi T, Moretta A, Lazzaro D, Costa P, Poli V, et al. Interleukin-6 causes growth impairment in transgenic mice through a decrease in insulin-like growth factor-I. A model for stunted growth in children with chronic inflammation. J Clin Invest 1997; 99 : 643-50.
42. 42 Kirschner BS, Sutton MM. Somatomedin-C levels in growth-impaired children and adolescents with chronic inflammatory bowel disease. Gastroenterology 1986; 91 : 166-76.
43. 43 Goulet O, Dabbas M, Blanche S. Retentissement nutritionnel de l'infection à VIH chez l'enfant. In: Melchior JC, Goulet O, éd. Nutrition et infection à VIH. Paris: Masson; 1997. p. 86-99.
44. 44 Rannels SR, Rannels DE, Pegg AE, Jefferson LS. Glucocorticoid effects on peptide-chain initiation in skeletal muscle and heart. Am J Physiol 1978; 235 : E134-9.
45. 45 Horber FF, Haymond MW. Human growth hormone prevents the protein catabolic effects of prednisone in humans. J Clin Invest 1990; 86 : 265-72.
46. 46 Scott AR, Danon M, Herrin J. Prednisone dose limitation of growth hormone treatment of steroid-induced growth failure. J Pediatr 1994; 125 : 322-5.
47. 47 Société française de pédiatrie. Comité de nutrition. Besoins en proteines des nourrissons et des enfants en bonne santé. Arch Pediatr 1997; 4 : 373-82.
48. 48 Millward DJ, Rivers JPW. The nutritional role of indispensable amino acids and the metabolic basis for their requirements. Eur J Clin Nutr 1988; 42 : 367-93.
49. 49 Jackson AA. Optimizing amino acid and protein supply and utilization in the newborn. Proc Nutr Soc 1989; 48 : 293-301.
50. 50 Sim AJW, Wolfe BM, Young VR, Clarke D, Moore FD. Glucose promotes whole-body protein synthesis from infused amino acids in fasting man. Lancet 1979; ii : 68-71.
51. 51 Shaw JMF, Klein S, Wolfe RR. Assessment of alanine, urea and glucose interrelationship in normal subjects and in patients with sepsis with stable isotopic tracers. Surgery 1985; 97 : 557-67.
52. 52 Wolfe RR, O'Donnell TF, Stone MD, Richmand DA, Burke JF. Investigations of factors determining the optimal glucose infusion rate in total parenteral nutrition. Metabolism 1980; 29 : 890-2.
53. 53 Greig PD, Elwyn DH, Askanazi J. Kinney JM. Parenteral nutrition in septic patients: effect of increasing nitrogen intake. Am J Clin Nutr 1987; 46 : 1040-7
54. 54 Long CL, Crosby F, Geiger JW, Kinney JM. Parenteral nutrition in the septic patient: nitrogen balance, limiting plasma amino acid and caloric to nitrogen ratios. Am J Clin Nutr 1976; 29 : 380-91.
55. 55 Jeevanadam M, Young DH, Schiller WR. Influence of parenteral nutrition on rates of net substrate oxydation in severe trauma patients. Crit Care Med 1990; 18 : 467-73.
56. 56 Michallet M, Carpentier F, Rullière C, Leverve X, Favier A, Denis MC, Denis et al. Définition et évolution du statut nutritionnel au cours d'une greffe osseuse allogénique. Nutr Clin Metabol 1988; 2 : 143-50.
57. 57 Furst P. Clinical application of 3-methylhistidine. In: Wesdorp RIC, Soeters PB, eds. Clinical Nutrition. London: Churchill Livingstone; 1982. p. 213-23.
58. 58 Goulet O, De Potter S, Salas J, Robert JJ, Rongier M, Benhariz M, et al. Leucine metabolism at graded amino acid intakes in children receiving patenteral nutrition. Am J Physiol 1993; 265 : E540-6.
59. 59 Mac Donald. Nutritional management of cystic fibrosis. Arch Dis Child 1996; 74 : 81-7.
60. 60 Green MR, Buchana E, Weawer LT. Nutritional management of the infant with cystic fibrosis. Arch Dis Child 1995; 72 : 452-6.
61. 61 Hildebrand H, Karlberg J, Kristianson B. Longitudinal growth in children and adolescents with inflammatory bowel disease. J Pediatr Gastroenterol Nutr 1994; 18 : 165-73.
62. 62 Kirschner B. Permanent growth failure in pediatric inflammatory bowel disease. J Pediatr Gastroenterol Nutr 1993; 16 : 368-9.
63. 63 McLain BI, Davidson PM, Stokes KB, Beasley SW. Growth after gut resection for Crohn's disease. Arch Dis Child 1991; 65 : 370-6.
64. 64 Goulet O, Dabbas M, Funck-Brentano I, Debré M. Prise en charge nutritionnelle au cours de l'infection à VIH chez l'enfant. In: Melchior JC, Goulet O, éd. Nutrition et infection à VIH. Paris: Masson; 1997. p. 157-73.
65. 65 Reilly JJ, Edwards CA, Weaver LT. Malnutrition in children with cystic fibrosis: the energy-balance equation. J Pediatr Gastroenterol Nutr 1997; 25 : 127-36.
66. 66 Skeie B, Kvetan V, Gil KM, Rothkopf MM, Newsholme EA, Askanazi J. Branch-chain amino acids: their metabolism and clinical utility. Crit Care Med 1990; 18 : 549-71.
67. 67 Corriol O. Solutés d'acides aminés en pédiatrie. Nutr Clin Metabol 1991; 1 : 17-30.
68. 68 Kirk SJ, Barbul A. Role of arginine in trauma, sepsis and immunity. J Parenter Enter Nutr 1990; 14 : S226-9.
69. 69 Cynober L, Vasson MP, Aussel C. Régimes enrichis en arginine: bases conceptuelles et données expérimentales. Nutr Clin Metabol 1996; 10 : 88-95.
70. 70 Daly JM, Leiberman MD, Goldfine MS, Shou J, Weintraub F, Rosato EF, et al. Enteral nutrition with supplemental arginine, RNA, and omega-3 fatty acids in patients after operation: immunologie, metabolic, and clinic outcome. Surgery 1992; 112 : 56-67.
71. 71 Kudsk KA, Minard G, Croce MA, Brown RO, Lowrey TS, Pritchard FE, et al. A randomized trial of isonitrogenous enteral diets after severe trauma: an immune-enhancing diet reduces septic complications. Ann Surg 1996; 224 : 531-43.
72. 72 Smith RJ. Glutamine metabolism and its physiologic importance. J Parenter Enter Nutr 1990; 14 : S40s-4.
73. 73 Millward DJ, Jepson MM, Omer A. Muscle glutamine concentration and protein turnover in vivo in malnutrition and in endotoxemia. Metabolism 1989; 38 : 6-13.
74. 74 Souba WW, Herskowitz K, Plumley DA. Lung glutamine metabolism. J Parenter Enter Nutr 1990; 14 : S68-70.
75. 75 Khan K, Hardy G, McElroy B, Elia M. The stability of L-glutamine in total parenteral nutrition solution. Clin Nutr 1991; 10 : 193-8.
76. 76 Vinnars E, Hammarqvist F, von der Decken A, Wernerman J. Role of glutamine and its analogs in posttraumatic muscle protein and amino acid metabolism. J Parenter Enteral Nutr 1990; 14 : S125-9.
77. 77 Palmer TE, Griffiths RD, Jones C. Effects of parenteral L-glutamine on muscle in the very severy ill. Nutrition 1996; 12 : 316-20.
78. 78 Griffiths RD, Jones C, Palmer TEA. Outcome and cost of intensive care patients given glutamine supplemented nutrition. Clin Nutr 1996; 15 Suppl 1 : 20 [abstract].
79. 79 Ziegler TR, Young LS, Benfell K, Scheltinga M, Hortos K, Bye R, et al. Clinical and metabolic efficacy of glutamine-supplemented parenteral nutrition after bone marrow transplantation: a randomized, double-blind, controlled study. Ann Intern Med 1992; 116 : 821-8.
80. 80 Lacey JM, Crouch JB Benfell K, Ringer SA, Wilmore CK, Maguire D, et al. The effects of glutamine supplemented parenteral nutrition in premature infants. J Parenter Enteral Nutr 1996; 20 : 74-80.
81. 81 Schloerb PR, Amare M. Total parenteral nutrition with glutamine in bone marrow transplantation and other clinical applications (a randomized, double blind study). J Parenter Enter Nutr 1993; 17 : 407-13.
82. 82 Furst P, Albres S, Stehle P. Availability of glutamine supplied intravenously as alanyl glutamine. Metabolism 1989; 38 : 67-72.
83. 83 Peterson B, Waller SO, Vinnars E, Wernerman J. Long term effect of glycyl-glutamine after elective surgery on free amino acids in muscle. J Parenter Enter Nutr 1994; 18 : 320-5.
84. 84 Tremel H, Kienle B, Weileman LS, Stehle P, Fürst P. Glutamine dipeptide-supplemented parenteral nutrition maintains intestinal fuction in the critically ill. Gastroenterology 1994; 107 : 1595-601.
85. 85 Van Zaanen HCT, Van der Lelie H, Timmer JG, Furst P, Sauerwein HP. Parenteral glutamine dipeptide supplementation does not ameliorate chemotherapy-induced toxicity. Cancer 1994; 74 : 2879-84.
86. 86 Long CL, Borghesi L, Stahl R, Clark JA, Geiger JW, DiRienzo DB, et al. Impact of enteral feeding of a glutamine-feeding of a glutamine supplemented formula on the hypoaminoacidemic response in trauma patients. J Trauma 1996; 40 : 97-102.
87. 87 Neu J, Roig JC, Meetze WH, Veerman M, Carter C, Millsaps M, et al. Enteral glutamine supplementation for very low birth weight infants decreases morbidity and hospital costs. J Pediatr 1997; 131 : 691-9.
88. 88 Lensen GL, Miller RH, Talabiska DG, Gianferante L. A double blind prospective randomized study of glutamine enriched compared with standard peptide-based feeding in critically ill patients. Am J Clin Nutr 1996; 64 : 615-21.
89. 89 Cynober L. Ornithine alpha-ketoglutarate. In: Cynober L. Amino-acid metabolism in health and nutritional disease. Boca Raton, FL: CRC Press; 1995. p. 385-98.
90. 90 Dumas F, De Bandt JP, Colomb V, Le Boucher J, Coudray-Lucas C, Lavie S, et al Enteral ornithine alpha-ketoglutarate enhances intestinal adaptation to massive resection in rats. Metabolism 1998; 47 : 1366-71.
91. 91 Cynober L, Lioret N, Coudray-Lucas C. Action of ornithine alpha-ketoglutarate on protein metabolism in burn patients. Nutrition 1987; 3 : 187-91.
92. 92 Wernerman J, Hammarqvist F, Vinnars E. Alpha-ketoglutarate and postoperative muscle catabolism. Lancet 1990; 335 : 701-3.
93. 93 Hammarqvist F, Wernerman J, von der Decker AN, Vinnars E. Alpha-ketoglutarate preserves protein synthesis and free glutamine in skeletal muscle after surgery. Surgery 1991; 109 : 28-36.
94. 93 Blomqvist BI, Hammartqvist F, von der Decken A, Wernerman J. Glutamine and a-ketoglutarate prevent the decrease in muscle free glutamine concentration and influence protein synthesis after total hip replacement. Metabolism 195; 44 : 1215-22.
95. 94 Moukarzel AA, Goulet O, Salas JS, Marti-Henneberg C, Buchman AL, Cynober L, et al. Growth retardation in children receiving long-term total parenteral nutrition: effects of ornithine alpha-ketoglutarate. Am J Clin Nutr 1994; 60 : 408-13.
96. 95 Woolfson AM, Heatley RV, Allisson SP. Insulin to inhibit protein catabolism after injury. N Engl J Med 1979; 300 : 14-7.
97. 96 Gelfand RA, Barrett EJ. Effect of physiologic hyperinsulinemia on skeletal muscle protein synthesis and breakdown in man. J Clin Invest 1987; 80 : 1-6.
98. 97 Manson JMK, Wilmore DW. Positive nitrogen balance with human growth hormone and hypocaloric intravenous feeding. Surgery 1986; 100 : 188-97.
99. 98 Jiang ZM, He SZ, Zhang SY, Wang XR, Yang NF, Zhu Y, et al. Low-dose growth hormone and hypocaloric nutrition attenuate the protein-catabolic response after major operation. Ann Surg 1989; 210 : 513-25.
100. 99 Ziegler TR, Young LS, Ferraril-Baliviera E, , Demling RH, Wilmore DW. Use of human growth hormone combined with nutritional support in a critical care unit. J Parenter Entereral Nutr 1990; 14 : 574-81.
101. 100 Ponting GA, Ward HC, Halliday D, Sim AJ. Protein and energy metabolism with biosynthetic human growth hormone in patients on full intravenous nutritional support. J Parenter Enteral Nutr 1990; 14 : 437-41.
102. 101 Gilpin DA, Barrow RE, Rutan RL, Broemeling L, Herndon DN. Recombinant human growth hormone accelerates wound healing in children with large cutaneous burns. Ann Surg 1994; 220 : 19-24.
103. 102 Dabbas M, Goulet O, Pinto G, Brauner R, Blanche S, Clapin A, et al. Recombinant human growth hormone therapy for cachexia in HIV-infected children. Clin Nutr 1998: 17 Suppl 1 : 16 (A).
104. 103 Guler HP, Zapf J, Froesh ER. Short-term metabolic effects of recombinant human insulin-like growth factor-I in healthy adults. N Engl J Med 1987; 317 : 137-40.
105. 104 Douglas RG, Gluckman PD, Breier BH, McCall JL, Parry B, Shaw JH. Effects of recombinant IGF-I on protein and glucose metabolism in rTNF-infused lambs. Am J Physiol 1991; 261 : E606-12.